Cipla Limited’s senior management has flagged up fiscal year 2023 as a potentially “big year” for generic launches in the US, while a marked uptick in demand for COVID-19 therapies amid the fierce second wave of the infectious disease in India is expected to translate into sharp gains for the company.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?